GO:0016068 type I hypersensitivity: Immediate Allergic Response, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016068 type I hypersensitivity is an inflammatory response driven by antigen recognition by antibodies bound to Fc receptors on mast cells or basophils, occurring within minutes after exposure of a sensitized individual to the antigen.
• The process leads to the release of inflammatory mediators such as histamines and lipid mediators, which cause vasodilation, bronchoconstriction, and other allergy symptoms.
• Key genes and proteins include FCER1A, MS4A2, KIT, TPSAB1, CMA1, HDC, and others that mediate mast cell and basophil activation.
• Type I hypersensitivity underlies allergic diseases such as asthma, allergic rhinitis, and anaphylaxis, and has been implicated in acute appendicitis.
• Research methods include knockout and knock-in mouse models, mast cell degranulation assays, and CRISPR screening to identify novel regulators.
• EDITGENE provides CRISPR services to create knockout, point-mutation, knock-in, and overexpression cell models for studying type I hypersensitivity genes.
Description
Type I hypersensitivity, also known as immediate hypersensitivity, is a rapid inflammatory response that occurs within minutes of allergen exposure in sensitized individuals. It is driven by the cross-linking of allergen-specific IgE antibodies bound to high-affinity Fc receptors on mast cells and basophils, leading to the release of histamine and other mediators. This process is central to allergic diseases such as asthma, allergic rhinitis, and anaphylaxis, and has been implicated in other conditions like acute appendicitis. Understanding the molecular and cellular mechanisms of type I hypersensitivity is crucial for developing therapeutic interventions and diagnostic tools. Researchers study this process using a variety of models, including gene-edited cell lines and animal models, to dissect the roles of individual genes and pathways. The integration of CRISPR-based gene editing with functional assays has accelerated the discovery of new targets and regulators of this response.
type I hypersensitivity At A Glance
| GO ID | GO:0016068 |
|---|---|
| GO term | type I hypersensitivity |
| Ontology | biological_process |
| Synonym | immediate hypersensitivity response |
| Major function | Rapid inflammatory response mediated by IgE and mast cells/basophils |
| Definition | An inflammatory response driven by antigen recognition by antibodies bound to Fc receptors on mast cells or basophils, occurring within minutes after exposure of a sensitized individual to the antigen, and leading to the release of a variety of inflammatory mediators such as histamines. |
| Related cell types | Mast cells, basophils |
| Key mediators | Histamine, lipid mediators, cytokines |
What Is GO:0016068?
Type I hypersensitivity is an inflammatory response driven by antigen recognition by antibodies bound to Fc receptors on mast cells or basophils, occurring within minutes after exposure of a sensitized individual to the antigen, and leading to the release of a variety of inflammatory mediators such as histamines.
Why Is type I hypersensitivity Important in Cell Biology?
Type I hypersensitivity is a fundamental biological process underlying allergic diseases that affect millions worldwide, including asthma, allergic rhinitis, and life-threatening anaphylaxis. It also plays a role in other inflammatory conditions such as acute appendicitis. Understanding its mechanisms is essential for developing targeted therapies and preventive strategies.
• Type I hypersensitivity mediates common allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis.
• It is responsible for anaphylaxis, a severe and potentially fatal systemic reaction.
• The process involves mast cell and basophil degranulation, releasing histamine and other mediators.
• Type I hypersensitivity has been implicated in the pathogenesis of acute appendicitis.
• It is a target for therapeutic interventions, including anti-IgE antibodies and mast cell stabilizers.
• Research on type I hypersensitivity informs vaccine design and allergy diagnostics.
• Genetic and environmental factors modulate susceptibility to type I hypersensitivity.
• CRISPR-based models enable precise dissection of gene function in this process.
What Happens During type I hypersensitivity?
Sensitization Phase
In simple terms: The first time the body meets an allergen, it prepares for future reactions.
During the sensitization phase, an individual is exposed to an allergen, leading to the production of allergen-specific IgE antibodies by B cells. These IgE antibodies bind to high-affinity FcεRI receptors on the surface of mast cells and basophils, arming them for future encounters. This phase is asymptomatic and can last for days to years.
Activation and Degranulation
In simple terms: When the allergen appears again, it triggers mast cells to release chemicals quickly.
Upon re-exposure, the allergen cross-links IgE antibodies bound to FcεRI on mast cells and basophils, causing receptor aggregation and intracellular signaling. This leads to the rapid release of preformed mediators such as histamine, proteases, and heparin from granules, a process known as degranulation. This occurs within minutes of allergen exposure.
Release of Lipid Mediators and Cytokines
In simple terms: Activated cells also produce other chemicals that prolong and amplify the reaction.
In addition to preformed mediators, activated mast cells synthesize and release lipid mediators such as prostaglandins and leukotrienes, as well as cytokines and chemokines. These mediators contribute to vasodilation, bronchoconstriction, mucus secretion, and recruitment of inflammatory cells, characterizing the late-phase response.
Physiological Effects
In simple terms: The chemicals cause symptoms like sneezing, itching, and difficulty breathing.
The released mediators act on various tissues, leading to symptoms such as vasodilation, increased vascular permeability, smooth muscle contraction, and mucus production. These effects manifest as allergic symptoms including urticaria, rhinitis, asthma, and in severe cases, anaphylactic shock.
Key Genes Involved in GO:0016068 type I hypersensitivity
The following genes and proteins are critically involved in the initiation and regulation of type I hypersensitivity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FCER1A | High-affinity IgE receptor alpha subunit | Target for anti-IgE therapies; knockout models reduce allergic responses |
| MS4A2 | FcεRI beta subunit, amplifies signaling | Mutations affect receptor stability and signaling; studied in mast cell lines |
| KIT | Receptor tyrosine kinase essential for mast cell development | Mutations cause mastocytosis; target for inhibitors |
| TPSAB1 | Tryptase alpha/beta-1, mast cell protease | Biomarker of mast cell activation; knockout mice show altered responses |
| CMA1 | Chymase, mast cell protease | Involved in tissue remodeling; studied in cardiovascular disease |
| HDC | Histidine decarboxylase, synthesizes histamine | Knockout mice lack histamine; used to study histamine-dependent responses |
| IL4 | Cytokine promoting Th2 responses and IgE class switching | Polymorphisms linked to allergy; overexpression models exacerbate inflammation |
| IL13 | Cytokine involved in allergic inflammation | Key mediator of asthma; targeted by biologics |
| STAT6 | Transcription factor downstream of IL-4/IL-13 | Knockout mice resist allergic inflammation |
| GATA2 | Transcription factor for mast cell differentiation | Haploinsufficiency affects mast cell numbers |
| FYN | Kinase involved in FcεRI signaling | Regulates degranulation; knockout studies show reduced responses |
| LYN | Kinase that both positively and negatively regulates FcεRI signaling | Knockout mice display hyperresponsive mast cells |
| SYK | Kinase essential for FcεRI signaling | Inhibitors block degranulation; knockout is lethal |
| PLCγ1 | Phospholipase C gamma 1, generates IP3 and DAG | Required for calcium flux and degranulation |
| PIK3CD | Phosphoinositide 3-kinase catalytic delta | Involved in mast cell survival and activation |
| TNF | Proinflammatory cytokine released by mast cells | Contributes to late-phase response; knockout reduces inflammation |
How Is type I hypersensitivity Regulated?
Type I hypersensitivity is tightly regulated at multiple levels. FcεRI signaling is modulated by kinases such as LYN and FYN, which can both activate and inhibit downstream pathways. Phosphatases like SHIP-1 and SHP-1 negatively regulate signaling to prevent excessive degranulation. Additionally, cytokines such as IL-4 and IL-13 amplify the response through STAT6-dependent transcription. Lipid mediators derived from arachidonic acid, including prostaglandins and leukotrienes, further modulate the intensity and duration of the reaction.
type I hypersensitivity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FCER1A | Allergic asthma | Knockout mouse or human mast cell line (LAD2) |
| IL4 | Atopic dermatitis | Overexpression transgenic mouse |
| IL13 | Allergic rhinitis | Knock-in mouse with human IL13 |
| TPSAB1 | Mastocytosis | Point mutation knock-in (e.g., D816V KIT) |
| HDC | Histamine-dependent anaphylaxis | Knockout mouse |
Allergic Asthma and Rhinitis
Type I hypersensitivity is the underlying mechanism of allergic asthma and rhinitis, where allergen exposure triggers mast cell degranulation and bronchoconstriction. Genetic variants in FCER1A, IL4, and IL13 are associated with asthma susceptibility.
Anaphylaxis
Anaphylaxis is a severe, systemic type I hypersensitivity reaction that can be life-threatening. It involves widespread mast cell activation and release of mediators causing hypotension, bronchospasm, and edema.
Acute Appendicitis
Recent studies suggest that type I hypersensitivity reactions may contribute to the development of acute appendicitis, with elevated IgE and mast cell infiltration observed in appendiceal tissue.
Hypersensitivity to Corticosteroids
Although rare, immediate hypersensitivity reactions to corticosteroids can occur, mediated by IgE mechanisms. These reactions can range from urticaria to anaphylaxis.
From type I hypersensitivity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate mast cell degranulation? | Knockout cell line (e.g., RBL-2H3) |
| Does a point mutation in KIT affect mast cell activation? | Point mutation knock-in mouse |
| Can overexpression of IL-4 exacerbate allergic inflammation? | Overexpression transgenic mouse |
| What is the role of FcεRI beta subunit in signaling? | Tagged knock-in for live-cell imaging |
| Identify novel regulators of type I hypersensitivity | CRISPR library screening in mast cells |
| Does a SNP in FCER1A alter IgE binding? | Knock-in humanized mouse |
How to Study the type I hypersensitivity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Beta-hexosaminidase release assay | Mast cell degranulation | In vitro drug screening |
| Passive cutaneous anaphylaxis | Vascular permeability in vivo | Testing anti-allergic drugs |
| Flow cytometry | Surface markers of activation | Diagnosing basophil activation |
| ELISA | Histamine, tryptase, cytokines | Measuring mediator release |
| CRISPR knockout screening | Gene function on a genome-wide scale | Identifying novel regulators |
| RNA-seq | Transcriptional changes upon activation | Pathway analysis |
| Proteomics | Protein expression and modifications | Signaling studies |
Mast Cell Degranulation Assays
Beta-hexosaminidase release assays are commonly used to measure mast cell degranulation in vitro. These assays quantify the release of granule contents following FcεRI cross-linking and are used to evaluate gene function.
CRISPR Screening
Genome-wide CRISPR knockout screens in mast cell lines can identify novel genes that regulate degranulation and cytokine production. Hits are validated using individual knockout lines and functional assays.
Passive Cutaneous Anaphylaxis
Passive cutaneous anaphylaxis (PCA) in mice is a classic in vivo model to assess type I hypersensitivity. It involves sensitizing the skin with IgE and challenging with antigen to measure vascular permeability.
Flow Cytometry and Imaging
Flow cytometry is used to quantify mast cell and basophil activation markers such as CD63 and CD203c. Imaging techniques like confocal microscopy visualize receptor clustering and granule release.
How CRISPR Can Be Used to Study GO:0016068 type I hypersensitivity
Knockout
CRISPR knockout of candidate genes in mast cell lines (e.g., LAD2, RBL-2H3) allows researchers to assess their role in degranulation and cytokine production. For example, knockout of SYK or PLCγ1 abolishes FcεRI-mediated signaling.
Point Mutation
Introducing specific point mutations (e.g., KIT D816V) using CRISPR base editing or HDR can model human diseases like mastocytosis and study their impact on mast cell activation.
Knock-in
Knock-in of reporter genes (e.g., GFP) or humanized alleles (e.g., human FCER1A) enables live-cell imaging and humanized mouse models for type I hypersensitivity research.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression of genes like IL4 or IL13 can create models of exacerbated allergic inflammation to study chronic responses.
How EDITGENE Supports type I hypersensitivity Research
Researchers studying type I hypersensitivity-related genes often need to determine whether a candidate gene is causally involved in mast cell activation, mediator release, or allergic inflammation. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell and animal models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for type I hypersensitivity research.
Frequently Asked Questions About type I hypersensitivity
What is type I hypersensitivity?
Type I hypersensitivity is an immediate allergic reaction mediated by IgE antibodies bound to mast cells and basophils, leading to the release of histamine and other mediators within minutes of allergen exposure.
What genes are involved in type I hypersensitivity?
Key genes include FCER1A, MS4A2, KIT, TPSAB1, CMA1, HDC, IL4, IL13, and STAT6, among others.
What are the symptoms of type I hypersensitivity?
Symptoms include sneezing, itching, urticaria, bronchoconstriction, and in severe cases, anaphylaxis.
How is type I hypersensitivity diagnosed?
Diagnosis involves skin prick tests, specific IgE blood tests, and basophil activation tests.
What is the difference between type I and type IV hypersensitivity?
Type I is immediate, IgE-mediated, and involves mast cells, while type IV is delayed, T-cell mediated, and peaks after 48-72 hours.
Can CRISPR be used to study type I hypersensitivity?
Yes, CRISPR knockout and knock-in models are widely used to dissect gene function in mast cell activation and allergic responses.
What are common research models for type I hypersensitivity?
Common models include RBL-2H3 and LAD2 mast cell lines, passive cutaneous anaphylaxis in mice, and humanized mouse models.
What mediators are released in type I hypersensitivity?
Histamine, tryptase, prostaglandins, leukotrienes, and cytokines such as TNF and IL-4 are released.
Is type I hypersensitivity involved in appendicitis?
Recent studies suggest a role for type I hypersensitivity in acute appendicitis, with mast cell infiltration and IgE involvement.
How can I create a knockout cell model for type I hypersensitivity research?
EDITGENE provides custom CRISPR knockout services in relevant cell lines, with validation and functional assays.
Conclusion
Type I hypersensitivity (GO:0016068) is a rapid and potent inflammatory response central to allergic diseases and anaphylaxis. Its molecular players, from FcεRI to histamine, are well-characterized and remain active targets for therapeutic development. Advances in CRISPR gene editing have enabled precise functional studies of these genes, accelerating the discovery of new treatments. EDITGENE supports this research with tailored gene-editing services, from knockout to overexpression models, empowering scientists to unravel the complexities of type I hypersensitivity.
References
- 1. Nakamura T. 2021. The roles of lipid mediators in type I hypersensitivity.. J Pharmacol Sci 147(1):126-131 PMID: 34294363
- 2. Vitte J et al.. 2022. Allergy, Anaphylaxis, and Nonallergic Hypersensitivity: IgE, Mast Cells, and Beyond.. Med Princ Pract 31(6):501-515 PMID: 36219943
- 3. Arredondo Montero J et al.. 2024. Role of type I hypersensitivity reaction in the development of overall and uncomplicated acute appendicitis: a systematic review and meta-analysis.. Curr Probl Surg 61(9):101551 PMID: 39168537
- 4. Vatti RR et al.. 2014. Hypersensitivity reactions to corticosteroids.. Clin Rev Allergy Immunol 47(1):26-37 PMID: 23567983
- 7. Rajani HF et al.. 2020. Protein and Antibody Engineering: Suppressing Degranulation of the Mast Cells and Type I Hypersensitivity Reaction.. Curr Protein Pept Sci 21(8):831-841 PMID: 32392111
- 8. Pan ZB et al.. 2023. Analysis of type I hypersensitivity-induced inflammatory response in children of different age groups with acute appendicitis.. Mol Immunol 158:103-106 PMID: 37182441
